These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 25526346)

  • 1. Mutational landscape of intrahepatic cholangiocarcinoma.
    Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
    Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
    Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
    Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profile of Intrahepatic Cholangiocarcinoma.
    Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
    Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
    World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
    Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E
    Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
    Peraldo-Neia C; Ostano P; Cavalloni G; Pignochino Y; Sangiolo D; De Cecco L; Marchesi E; Ribero D; Scarpa A; De Rose AM; Giuliani A; Calise F; Raggi C; Invernizzi P; Aglietta M; Chiorino G; Leone F
    BMC Genomics; 2018 Jun; 19(1):440. PubMed ID: 29871612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
    Nepal C; O'Rourke CJ; Oliveira DVNP; Taranta A; Shema S; Gautam P; Calderaro J; Barbour A; Raggi C; Wennerberg K; Wang XW; Lautem A; Roberts LR; Andersen JB
    Hepatology; 2018 Sep; 68(3):949-963. PubMed ID: 29278425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
    Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
    Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
    Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
    J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast.
    Kamikawa T; Amenomori M; Itoh T; Momoi H; Hiai H; Machinami R; Ishikawa Y; Mori T; Shimahara Y; Yamaoka Y; Fukumoto M
    Radiat Res; 1999 Dec; 152(6 Suppl):S118-24. PubMed ID: 10564951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.